What can St. Jude expect post-Riata?

How concerned is Wall Street about St Jude Medical's ($STJ) heart rhythm devices? Very, especially since physicians might now think twice about using the company's heart devices (bear in mind, there's a $6.5 billion worldwide market for implantable defibrillators at stake). "I stopped using Durata months ago. I stopped using Riata years ago," Reuters quotes one doctor as saying--and those words can't make the company feel much better. "People are wondering, is there more to this story? When you see such a vigorous defense, you wonder what's evoking this? Why are they fighting people who are raising questions? This could leave lasting reputational damage," said Dr. Harlan Krumholz, a cardiologist at the Yale School of Medicine. Analysis

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.